Backed by eight human clinical trials and capable of targeting stress, mood, and sleep support, the introduction of the postbiotic to ADM’s portfolio comes as products targeting mood/relaxation support
ADM, a global leader in innovative solutions from nature, announced its agreement with Asahi Group Foods Corporation, a leading food company headquartered in Japan, to exclusively market and distribute Asahi Group’s proprietary lactic acid-based postbiotic, Lactobacillus gasseri CP2305. Backed by eight human clinical trials and capable of targeting stress, mood, and sleep support, the introduction of the postbiotic to ADM’s portfolio comes as products targeting mood/relaxation support grew at a double-digit CAGR of 13 per cent from 2018-2023, with a category growth of nearly 34 per cent.
“Stress, mood and sleep are among the fastest-growing wellness segments, and – as the cornerstone to physical and emotional health – they are also some of the most disruptive factors to everyday life and overall well-being if not properly supported,” said Mark Lotsch, ADM’s President of Global Health & Wellness. “Our agreement with pioneering Asahi Group to bring science-backed L. gasseri CP2305 postbiotic into our robust health and wellness solutions library is a critical step in advancing new product development to support consumers’ quality of life around the world.”
“The addition of L. gasseri CP2305 builds upon our postbiotics suite, reinforcing our leadership and dedication to delivering resilient ingredients with strong results for various areas of health and well-being,” said Lotsch. “With these science-backed ingredients, we’re looking forward to helping usher in what’s next in functional foods to support the evolving wellness goals of consumers across regions.”
